
Freenome aims to take on the big beasts
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.

Liquid biopsy developers take aim at colorectal cancer
Natera and Guardant are about to shake things up with indication-specific blood tests, but Exact is keeping faith with Cologuard – for now.

With its liquid biopsy approval, Foundation Medicine takes on Guardant
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.

How best to develop a liquid biopsy?
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.

2019 was all about execution for smaller device makers
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.